OLD Point Trust & Financial Services N A Sells 1,760 Shares of Pfizer Inc. $PFE

OLD Point Trust & Financial Services N A lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,463 shares of the biopharmaceutical company’s stock after selling 1,760 shares during the period. OLD Point Trust & Financial Services N A’s holdings in Pfizer were worth $1,514,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at approximately $27,000. Bayforest Capital Ltd bought a new position in Pfizer during the 1st quarter valued at approximately $28,000. North Capital Inc. bought a new position in Pfizer during the 1st quarter valued at approximately $28,000. WPG Advisers LLC bought a new position in Pfizer during the 1st quarter valued at approximately $35,000. Finally, Horizon Financial Services LLC bought a new stake in shares of Pfizer in the 1st quarter worth $35,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Performance

PFE stock opened at $25.46 on Wednesday. The company has a market cap of $144.75 billion, a P/E ratio of 13.54, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s fifty day moving average price is $24.55 and its 200-day moving average price is $24.11.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.